Mielóma multiplex: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 3
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• TIGIT 0
• AMPK 0
• B7-H3 0
• NRAS 1
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

99+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R01

  Modulation of Bone Formation and Fracture Repair During Cancer Development

  Washington University· Saint Louis, Egyesült Államok· 577 398 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R50

  Curing Through Cooperation: Aligning Cooperative Groups to Investigate Novel Therapeutic Approaches to Cure Plasma Cell Dyscrasias

  Utah State Higher Education System--University of Utah· Salt Lake City, Egyesült Államok· 173 767 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R44

  Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma

  Cellsbin, Inc.· Branford, Egyesült Államok· 1 045 925 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · U01

  Comparative Modeling of Multiple Myeloma Prevention, Early Detection and Treatment Interventions

  Washington University· Saint Louis, Egyesült Államok· 848 978 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Overcoming CAR T cell resistance by tumor-restricted IL-12 driven anti-tumor immunity

  University of California Los Angeles· Los Angeles, Egyesült Államok· 477 666 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Németország· EU contribution 1 466 571 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spanyolország· EU contribution 9 998 178 EUR· until 2031. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Németország· EU contribution 9 999 253 EUR· until 2028. máj.· 8 countries

10 of 332 running projects, newest first. Listed amounts together: 252,1 M USD + 35,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

  NCT06691685· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Frissítve: 2026. júl. 22.

  “The collaborator EsoBiotec was acquired by AstraZeneca.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

  NCT04318327· Novartis Pharmaceuticals· Frissítve: 2026. júl. 9.

  “Business decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

  NCT05498545· Second Affiliated Hospital of Xi'an Jiaotong University· Frissítve: 2026. jún. 16.

  “Achieved the proof of concept”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

  NCT07340853· Thomas Martin, MD· Frissítve: 2026. jún. 11.

  “Safety Review”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment

  NCT07195617· Guangzhou Bio-gene Technology Co., Ltd· Frissítve: 2026. máj. 28.

  “Due to corporate strategic adjustment.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

  NCT07196124· Guangzhou Bio-gene Technology Co., Ltd· Frissítve: 2026. máj. 28.

  “Due to corporate strategic adjustment.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

  NCT06698744· David Wald· Frissítve: 2026. máj. 13.

  “Replaced by study by different sponsor”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

  NCT06663046· Wondercel Biotech (ShenZhen)· Frissítve: 2026. máj. 7.

  “Because the implementation of the new regulation policy by the Chinese authority”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

  NCT05846737· Institute of Hematology & Blood Diseases Hospital, China· Frissítve: 2026. ápr. 29.

  “The study was withdrawn due to the inability to enroll participants.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

  NCT05090566· Pfizer· Frissítve: 2026. ápr. 24.

  “A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Pfizer· Forrás

• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  NCT05828511· Regeneron Pharmaceuticals· Forrás

• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Regeneron Pharmaceuticals· Forrás

• A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT07455851· Regeneron Pharmaceuticals· Forrás

• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

  NCT05137054· Regeneron Pharmaceuticals· Forrás

• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Regeneron Pharmaceuticals· Forrás

• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Regeneron Pharmaceuticals· Forrás

• Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03145181· Janssen Research & Development, LLC· Forrás

• A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

  NCT04133636· Janssen Research & Development, LLC· Forrás

• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Janssen Research & Development, LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Patient-derived organoids in hematologic malignancies: Fidelity and translation beyond animals.

  Trends Cancer, 2026. jún.

• The rise of bone marrow organoids as next-generation models for blood formation and failure.

  Exp Hematol, 2026. ápr.

• comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.

  Cell Stem Cell, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.